lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Supplementary Protection Certificates: still a grey area?
Stockholm University.ORCID iD: 0000-0003-1211-4972
2016 (English)In: Journal of Intellectual Property Law & Practice, ISSN 1747-1532, Vol. 11, no 5, p. 372-381Article in journal (Refereed) Published
Abstract [en]

Supplementary Protection Certificates (SPCs) were introduced in 1992, and have since been considered a very valuable tool for the pharmaceutical industry, allowing for market prolongation and compensating for the effective patent protection time lost in the process of market authorization.

Over the past five years, numerous Court of Justice of the European Union (CJEU) rulings have attempted to interpret the provisions of EU Regulation 1901/2009 and provide clarity to patent holders as well as generics manufacturers as to the protection requirements and the scope of protection awarded. This article analyses the implication of major CJEU cases concerning the interpretation of Articles 3(a), 3(d) and 1(b) of the Regulation.

The article also discusses the interrelation between the EU SPC Regulation, on the one hand, and the Market Authorization Regulation and the Market Authorization Directive, on the other, and compares the EU system with that provided by the USA. An analysis of recent case law reveals that now, some 25 years after the entry into force of the Regulation, the system is still obscure. A serious concern also arises as to whether the system as it stands today is simply inappropriate to the protection of modern pharmaceuticals and whether this is also one of the reasons for the growing volume of case law in the field.

Place, publisher, year, edition, pages
Oxford University Press, 2016. Vol. 11, no 5, p. 372-381
Keywords [en]
patents, pharmaceuticals, supplementary protection
National Category
Law (excluding Law and Society)
Research subject
Law; Law
Identifiers
URN: urn:nbn:se:lnu:diva-65001DOI: 10.1093/jiplp/jpw027ISI: 000403091600006OAI: oai:DiVA.org:lnu-65001DiVA, id: diva2:1107016
Available from: 2017-06-08 Created: 2017-06-08 Last updated: 2018-05-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Papadopoulou, Frantzeska

Search in DiVA

By author/editor
Papadopoulou, Frantzeska
Law (excluding Law and Society)

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 38 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf